Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARGENZA vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
FDA-approved: In combination with chemotherapy (capecitabine or gemcitabine plus cisplatin) for the treatment of adults with metastatic or locally advanced unresectable HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received two or more prior anti-HER2 regimens.,Off-label: Not specified in FDA labeling; potential off-label uses may include other HER2-positive malignancies, but none are established.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Margetuximab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes or pathways are involved.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
~99% bound to plasma proteins, primarily to albumin and immunoglobulin G (as a monoclonal antibody).
Approximately 20–30% bound to plasma proteins.
Volume of distribution approximately 3.0-4.0 L (0.04-0.06 L/kg). Low Vd indicates limited extravascular distribution, consistent with large antibody molecule primarily confined to plasma and interstitial space.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Bioavailability is 100% by intravenous route as it is administered as an IV infusion; not available for oral or other routes.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No dose adjustment recommended for mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin >1-1.5× ULN with any AST). Not studied in moderate (total bilirubin >1.5-3× ULN with any AST) or severe (total bilirubin >3× ULN with any AST) hepatic impairment.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and effectiveness in pediatric patients have not been established.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended. Of the 292 patients treated with MARGENZA in the SOPHIA trial, 45% were aged 65 years or older, 11% were 75 or older. No overall differences in efficacy or safety observed between elderly and younger patients.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
No black box warning exists for MARGENZA.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Cardiotoxicity: Left ventricular ejection fraction (LVEF) decline; assess LVEF prior to and during treatment. Discontinue for symptomatic heart failure or persistent decline.,Infusion-related reactions: Monitor during infusion; reduce rate or discontinue for severe reactions.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of the risk and use effective contraception.,Pulmonary toxicity: Interstitial lung disease and pneumonitis; monitor for signs/symptoms and permanently discontinue if confirmed.,Neutropenia and febrile neutropenia: May occur; monitor blood counts.,Hypokalemia and hypomagnesemia: Monitor electrolytes and replace as needed.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None known.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions are known. No dietary restrictions required during treatment.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
MARGENZA (margetuximab-cmkb) is an Ig G1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted agents, it is expected to cause fetal harm or death when administered to a pregnant woman. Human Ig G molecules cross the placenta, with increasing transfer as pregnancy progresses, reaching peak levels during the third trimester. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may have lower risk, but second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, and fetal loss.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
There are no data on the presence of margetuximab in human milk, its effects on the breastfed infant, or its effects on milk production. Maternal Ig G is present in human milk, but the amount of margetuximab transferred is expected to be low due to its large molecular size. However, because of the potential for serious adverse reactions in nursing infants, women should discontinue breastfeeding during treatment and for at least 4 months after the last dose. M/P ratio is not available.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No dosage adjustment is recommended for MARGENZA based on pregnancy-induced pharmacokinetic changes; however, the drug should be avoided during pregnancy due to fetal harm. No specific pharmacokinetic studies have been conducted in pregnant women to warrant dose adjustments.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
MARGENZA (margetuximab-cmkb) is an anti-HER2 monoclonal antibody indicated in combination with chemotherapy for metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens. Premedicate with acetaminophen, diphenhydramine, and corticosteroids to mitigate infusion-related reactions. Monitor for left ventricular ejection fraction (LVEF) decline; assess cardiac function at baseline and every 3 months during treatment. Use with caution in patients with prior anthracycline exposure or pre-existing cardiac dysfunction.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
MARGENZA is given as an intravenous infusion every 3 weeks; each infusion takes about 90 minutes initially, then 30 minutes if well tolerated.,You may experience infusion-related reactions such as fever, chills, or nausea; you will receive premedication to reduce these.,This drug can cause heart problems; your doctor will monitor your heart function with echocardiograms regularly.,MARGENZA can cause fetal harm if used during pregnancy; use effective contraception during treatment and for 4 months after the last dose.,Do not breastfeed during treatment and for 4 months after the last dose.,Common side effects include fatigue, nausea, diarrhea, and anemia.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARGENZA vs CLADRIBINE, answered by our medical review team.
MARGENZA is a Antineoplastic Agent that works by Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARGENZA and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARGENZA is: 15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARGENZA and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARGENZA is classified as Category C. MARGENZA (margetuximab-cmkb) is an IgG1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.